Bioimpedance Analysis Guided Volume Expansion for the Prevention of Contrast Induced-acute Kidney Injury (BELIEVE)

August 31, 2017 updated by: Mahidol University

Bioimpedance Analysis Guided Volume Expansion for the Prevention of Contrast

Bioelectrical impedance analysis guided volume expansion for the prevention of contrast induced-acute kidney injury

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Compared bioelectrical impedance analysis guided hydration therapy versus standard hydration for the prevention of contrast induced-acute kidney injury

Study Type

Interventional

Enrollment (Actual)

56

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 18-90 yr
  2. Chronic kidney disease stage 3 & 4 (eGFR 15-60 ml/min/m2)
  3. elective cardiac catheterization

Exclusion Criteria:

  1. Contrast media administration in the past 14 days
  2. congestive heart failure (NYHA III-IV, ascites , pleuropericardial effusion ,severe valvular heart disease
  3. Kidney transplant status or RRT
  4. Emergency cardiac catheterization
  5. Allergy to radiographic contrast media
  6. Unstable renal function (change in serum creatinine ≥ 0.5 mg/dl or 25% within 14 days prior to the study
  7. Not inform consent
  8. left ventricular ejection fraction < 40 %
  9. Liver cirrhosis child B or C
  10. Dosage of angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker changed in past 2 wk

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Control
standard hydration : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
Other: standard hydration
standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
Experimental: Bioimpedance guided

Bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water

  • extracellular water/total body water < 0.36 : 4 ml/kg/hr
  • extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr
  • extracellular water/total body water > 0.4 : 1 ml/kg/hr
Other: Bioimpedance guided

bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water

  • extracellular water/total body water < 0.36 : 4 ml/kg/hr
  • extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr
  • extracellular water/total body water > 0.4 : 1 ml/kg/hr

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
serum creatinine at 48-72 hours after contrast administration
Time Frame: 48-72 hr
Acute kidney injury
48-72 hr

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
serum creatinine at 2 weeks after contrast administration
Time Frame: 2 weeks
Renal replacement therapy
2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mahidol University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2015

Primary Completion (Actual)

January 1, 2016

Study Completion (Actual)

January 1, 2016

Study Registration Dates

First Submitted

May 17, 2015

First Submitted That Met QC Criteria

May 19, 2015

First Posted (Estimate)

May 20, 2015

Study Record Updates

Last Update Posted (Actual)

September 1, 2017

Last Update Submitted That Met QC Criteria

August 31, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2558/171

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe